EMA/193790/2021

European Medicines Agency decision
P/0202/2021

of 10 May 2021

on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for respiratory syncytial virus stabilised prefusion f subunit vaccine (RSVpreF) (EMEA-002795-PIP01-20) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.
European Medicines Agency decision
P/0202/2021

of 10 May 2021

on the agreement of a paediatric investigation plan and on the granting of a deferral and on the
granting of a waiver for respiratory syncytial virus stabilised prefusion f subunit vaccine (RSVpreF)
(EMEA-002795-PIP01-20) in accordance with Regulation (EC) No 1901/2006 of the European
Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of
12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC)

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of
31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal
products for human and veterinary use and establishing a European Medicines Agency²,

Having regard to the application submitted by Pfizer Europe MA EEIG on 24 March 2020 under
Article 16(1) of Regulation (EC) No 1901/2006 also requesting a deferral under Article 20 of said
regulation and a waiver under Article 13 of said Regulation,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on
26 March 2021, in accordance with Article 17 of Regulation (EC) No 1901/2006 and Article 21 of said
Regulation and Article 13 of said Regulation,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

(1) The Paediatric Committee of the European Medicines Agency has given an opinion on the
agreement of a paediatric investigation plan and on the granting of a deferral and on the
granting of a waiver.

(2) It is therefore appropriate to adopt a decision agreeing a paediatric investigation plan.

(3) It is therefore appropriate to adopt a decision granting a deferral.

(4) It is therefore appropriate to adopt a decision granting a waiver.

Has adopted this decision:

**Article 1**

A paediatric investigation plan for respiratory syncytial virus stabilised prefusion f subunit vaccine (RSVpreF), powder and solvent for solution for injection, intramuscular use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby agreed.

**Article 2**

A deferral for respiratory syncytial virus stabilised prefusion f subunit vaccine (RSVpreF), powder and solvent for solution for injection, intramuscular use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

**Article 3**

A waiver for respiratory syncytial virus stabilised prefusion f subunit vaccine (RSVpreF), powder and solvent for solution for injection, intramuscular use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

**Article 4**

This decision is addressed to Pfizer Europe MA EEIG, Boulevard de la Plaine 17, 1050 – Brussels, Belgium.
Opinion of the Paediatric Committee on the agreement of a Paediatric Investigation Plan and a deferral and a waiver
EMEA-002795-PIP01-20

Scope of the application

Active substance(s):
Respiratory syncytial virus stabilised prefusion f subunit vaccine (RSVpreF)

Condition(s):
Prevention of lower respiratory tract disease caused by respiratory syncytial virus via maternal immunisation

Pharmaceutical form(s):
Powder and solvent for solution for injection

Route(s) of administration:
Intramuscular use

Name/corporate name of the PIP applicant:
Pfizer Europe MA EEIG

Basis for opinion

Pursuant to Article 16(1) of Regulation (EC) No 1901/2006 as amended, Pfizer Europe MA EEIG submitted for agreement to the European Medicines Agency on 24 March 2020 an application for a paediatric investigation plan for the above mentioned medicinal product and a deferral under Article 20 of said Regulation and a waiver under Article 13 of said Regulation.

The procedure started on 30 April 2020.

Supplementary information was provided by the applicant on 21 December 2020. The applicant proposed modifications to the paediatric investigation plan.
Opinion

1. The Paediatric Committee, having assessed the proposed paediatric investigation plan in accordance with Article 17 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:
   - to agree the paediatric investigation plan in accordance with Article 17(1) of said Regulation;
   - to grant a deferral in accordance with Article 21 of said Regulation;
   - to grant a waiver for one or more subsets of the paediatric population in accordance with Article 13 of said Regulation and concluded in accordance with Article 11(1)(b) of said Regulation, on the grounds that the disease or condition for which the specific medicinal product is intended does not occur in the specified subset(s) of the paediatric population.

   The Norwegian Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the agreed paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annex and appendix.
Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)
1. Waiver

1.1. Condition:

Prevention of lower respiratory tract disease caused by respiratory syncytial virus via maternal immunisation

The waiver applies to:

- males from birth to less than 18 years of age and females from birth to before menarche;
- powder and solvent for solution for injection, intramuscular use;
- on the grounds that the disease or condition for which the specific medicinal product is intended does not occur in the specified paediatric subset(s).

2. Paediatric investigation plan

2.1. Condition:

Prevention of lower respiratory tract disease caused by respiratory syncytial virus via maternal immunisation

2.1.1. Indication(s) targeted by the PIP

Prevention of lower respiratory tract disease caused by respiratory syncytial virus via maternal immunisation

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

Females from menarche to less than 18 years of age.

2.1.3. Pharmaceutical form(s)

Powder and solvent for solution for injection

2.1.4. Measures

<table>
<thead>
<tr>
<th>Area</th>
<th>Number of measures</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Quality-related studies</td>
<td>0</td>
<td>Not applicable.</td>
</tr>
<tr>
<td>Non-clinical studies</td>
<td>0</td>
<td>Not applicable.</td>
</tr>
<tr>
<td>Area</td>
<td>Number of measures</td>
<td>Description</td>
</tr>
<tr>
<td>-------------------------------------------</td>
<td>--------------------</td>
<td>-----------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Clinical studies</td>
<td>1</td>
<td>Study 1 (C3671011) Multicenter, randomised, double-blind placebo-controlled trial to assess safety, tolerability and immunogenicity of respiratory syncytial virus stabilised prefusion f subunit vaccine (RSVpreF) in healthy non-pregnant girls from menarche to less than 18 years of age (and non-pregnant adult women).</td>
</tr>
<tr>
<td>Extrapolation, modelling and simulation studies</td>
<td>0</td>
<td>Not applicable.</td>
</tr>
<tr>
<td>Other studies</td>
<td>0</td>
<td>Not applicable.</td>
</tr>
<tr>
<td>Other measures</td>
<td>0</td>
<td>Not applicable.</td>
</tr>
</tbody>
</table>

### 3. Follow-up, completion and deferral of PIP

<table>
<thead>
<tr>
<th>Concerns on potential long term safety/efficacy issues in relation to paediatric use:</th>
<th>No</th>
</tr>
</thead>
<tbody>
<tr>
<td>Date of completion of the paediatric investigation plan:</td>
<td>By March 2026</td>
</tr>
<tr>
<td>Deferral for one or more measures contained in the paediatric investigation plan:</td>
<td>Yes</td>
</tr>
</tbody>
</table>